The effect of high dose losartan on erythropoietin resistance in patients undergoing haemodialysis

Odabas A., Cetinkaya R., Selcuk Y., Keles S., Bilen H.

PANMINERVA MEDICA, vol.45, no.1, pp.59-62, 2003 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 45 Issue: 1
  • Publication Date: 2003
  • Journal Name: PANMINERVA MEDICA
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.59-62
  • Keywords: anaemia, erythropoietin, renal dialysis, angiotensin converting enzyme inhibitors, CHRONIC-RENAL-FAILURE, CONVERTING ENZYME-INHIBITORS, C-REACTIVE PROTEIN, POSTTRANSPLANT ERYTHROCYTOSIS, HEMODIALYSIS-PATIENTS, ANEMIA, ENALAPRIL, DIALYSIS, REQUIREMENTS, VOLUNTEERS
  • Akdeniz University Affiliated: No

Abstract

Aim. In some of the patients undergoing haemodialysis, (HD) resistance might develop against recombinant human erythropoietin (rHuEPO) used for treatment of anaemia. Recently, angiotensin-converting enzyme (ACE) inhibitors that are used to treat hypertension and congestive heart failure in HD patients have been suggested to contribute to anaemia as well by inhibiting erythropoiesis. Our purpose in this study is to investigate whether or not losartan, an angiotensin II (ATII) receptor antagonist, is causing rHuEPO resistance.